Acer aims for public listing through reverse merger

Struggling biotech Opexa gets a lift for shareholders as Acer takes over its shell.

By Suzanne Elvidge • July 7, 2017

Konica Minolta buys US genetic test maker in $1B deal

The Japanese imaging firm aims to play a bigger role in precision medicine and adding Ambry Genetics will give it the genetic testing capabilities it needs. 

By Suzanne Elvidge • July 7, 2017

Celgene makes play to strengthen PD-1 position

The big biotech is buying its way further into the PD-1 race through a deal with China's BeiGene. 

By Lisa LaMotta • July 6, 2017

Oxford BioMedica, Novartis link up on CAR-T drug production

The deal could provide more than $100 million to the U.K.-based gene therapy developer as well as long-term profitability, according to analysts.

By Jacob Bell • July 6, 2017

Roche snaps up diabetes startup mySugr

MySugr recently recorded its one millionth registered user on its digital diabetes management platform. 

By Suzanne Elvidge • July 5, 2017

Prescribed Reading: Gottlieb pushes for efficiency at FDA

The Chief is trying to fulfill promises, while deal activity continues to stagnate in the sector as the industry waits on news from Washington. 

By Lisa LaMotta • June 30, 2017

Prescribed Reading: What we know from BIO

A closer look at the trends everyone was talking about at BIO, FDA continues its approval spree and Novartis has heart. 

By Lisa LaMotta • June 23, 2017

Cell Medica boosts manufacturing capacity in cell therapy deal

The U.K. cell therapy company hopes to push forward with development of CGT Catapult's WT1 targeting T-cell receptor technology. 

By Suzanne Elvidge • June 21, 2017

Pricing pressures lower drug sales forecasts, new report finds

It was the first lowering of long-term sales expectations in the 10-year history of EvaluatePharma's World Preview reports.

By Jacob Bell • June 21, 2017

Report: Biopharma dealmaking set to level off

A new survey from InVentiv Health suggests 2017 may see M&A levels closer to recent historical norms rather than the peak seen in 2015.

By Ned Pagliarulo • June 21, 2017

Private equity firm snaps up Parexel

Pamplona Capital's $5 billion deal for Parexel is the latest in a string of takeovers and mergers that have shaken up the contract research space.

By Suzanne Elvidge • June 21, 2017

#BIO2017 Day 1 roundup: Saunders' popularity and BI's strategy

The first day of the Biotechnology Innovation Center conference kicked off in San Diego, attracting thousands of industry participants to the sunny convention center. 

By Lisa LaMotta • June 19, 2017

Prescribed Reading: ADA, Mylan, and an executive order?

The SGLT-2 category heats up at ADA, Mylan faces pressure from all sides, and President Trump might put his stamp on drug pricing.

By Lisa LaMotta • June 16, 2017

Pfizer builds out anti-infective reach with Basilea deal

The pharma giant has picked up commercialization rights for Basilea's Cresemba in Europe, adding another product to its ex-U.S. portfolio.

By Suzanne Elvidge • June 16, 2017

New deal should help Baxter speed up generic injectables development

The agreement with Dorizoe Lifesciences covers more than 20 treatments for cancer, cardiovascular disease or infections.

By Jacob Bell • June 15, 2017

Novartis, Verily back new $300M fund for European biotechs

Investment firm Medicxi launched the new fund to address a lack of "growth capital" for European biotechs that have moved beyond early-stage research. 

By Ned Pagliarulo • June 15, 2017

JSR snaps up cell line developer

Japanese life sciences company JSR has hooked cell line developer Selexis to create a 'gene to GMP' service.

By Suzanne Elvidge • June 15, 2017

Celgene swoops in on cancer collaboration with Dragonfly

Young startup Dragonfly Therapeutics scored a major partner in a five-year collaboration aimed at bringing its natural killer cell technology to Celgene's pipeline.

By Suzanne Elvidge • June 12, 2017

Regulus reports a trio of pipeline setbacks

The maker of microRNA therapies terminated two clinical programs, including one for its lead candidate, and revealed that AstraZeneca is pulling out of development for a third candidate.

By Jacob Bell • June 12, 2017

Prescribed Reading: June filled with divestitures and data

Conference season is in full swing for the industry, big pharma is selling off assets and the FDA is making some surprising moves. 

By Lisa LaMotta • June 9, 2017

AMRI valued at $930M in takeout offer

The Carlyle Group and GTCR agreed to pay $21.75 per outstanding share of the contract research and manufacturing organization.

By Jacob Bell • June 8, 2017

Roche drops NewLink IDO inhibitor after ASCO

The big pharma is bowing out of a hot area in cancer, setting up its former biotech partner for a rough road ahead. 

By Lisa LaMotta • June 8, 2017

Lilly drops $55M for access to new class of diabetes drugs

The big drugmaker locked down worldwide rights to a handful of dual amylin calcitonin receptor agonists through a new deal with KeyBioscience.

By Jacob Bell • June 8, 2017

Valeant makes latest divestment as business unravels

The beleaguered specialty pharma is selling off another piece of its business in an attempt to pay down debt. 

By Lisa LaMotta • June 8, 2017

Kamada slumps after Shire hands back rights

Kamada investors show concern as Shire backs out of a graft-versus-host disease study. 

By Suzanne Elvidge • June 8, 2017